SPIKEVAX LP.8.1 ser pré 50 µg 1 pce

7680702050010 CH-70205 J07BN01 08.08.

No images available

Details

Product number
7020501
CPT
-
Packaging group
1
Unit
Fertigspritze(n)
Composition
Suspension: SARS-CoV-2 LP.8.1 mRNA 50 µg pro dosi, heptadecan-9-ylis 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)-octanoas, cholesterolum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, 1,2-dimyristoyl-rac-glycero-3-polyethylenglycoli 2000 aether methylicus, trometamolum, trometamoli hydrochloridum, acidum aceticum, natrii acetas trihydricus, saccharum, aqua ad iniectabile, pro dosi, natrium 0.017 mg pro dosi.

Articles (1)

Spikevax LP.8.1
LP.8.1
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
31/10/2025
Professional SmPC
Français
31/10/2025
Professional SmPC
Italien
31/10/2025
Patient information leaflet
Allemand
07/08/2025
Patient information leaflet
Français
07/08/2025
Patient information leaflet
Italien
07/08/2025

Detailed composition

Substance Quantity Type Category
SARS-CoV-2 LP.8.1 mRNA
50.0 UG Substance Wirkstoff (Principe actif)
heptadecan-9-ylis 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)-octanoas
- Substance HNIDK
cholesterolum
- Substance HNIDK
1,2-distearoyl-sn-glycero-3-phosphocholinum
- Substance HNIDK
1,2-dimyristoyl-rac-glycero-3-polyethylenglycoli 2000 aether methylicus
- Substance HNIDK
trometamolum
- Substance HNIDK
trometamoli hydrochloridum
- Substance HNIDK
acidum aceticum
- Substance HNIDK
natrii acetas trihydricus
- Substance HNIDK
saccharum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
0.017 MG Substance HBESI

Authorization holder

Moderna Switzerland GmbH

4052 Basel

Authorization information

Swissmedic authorization number
70205
Drug name
Spikevax LP.8.1
Galenic form
DISIJ
ATC Code
J07BN01
Authorization status
Z
Dispensation category
B
First authorization
06/08/2025
Authorization expiration date
05/08/2030
IT number
08.08.
Domain
Human medicine
Field of application
Spikevax LP.8.1 ist für die aktive Immunisierung zur Vorbeugung der durch das SARS-CoV-2-Virus verursachten Coronavirus-2019-Erkrankung (COVID-19) bei Personen ab 12 Jahren indiziert.

Packaging details

Description (FR)
SPIKEVAX LP.8.1 ser pré 50 µg 1 pce
Description (DE)
SPIKEVAX LP.8.1 Fertspr 50 µg 1 Stk
Market launch
27/08/2025
Narcotic (BTM)
No

Other packaging sizes

SPIKEVAX LP.8.1 ser pré 50 µg 10 pce
10 FESP
GTIN: 7680702050027
View
Buy us a coffee Explore the data